Skip to main content

BioXcel Therapeutics, Inc.

BTAIQ
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001720893

No open-market purchases or sales by BioXcel Therapeutics, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $8.69M in total; Oaktree Capital is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by BioXcel Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for BioXcel Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for BioXcel Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Atkins Susan E.Director–Aug 14, 20261
Steinhart Richard IChief Financial Officer26,335Jun 17, 20266
Yocca FrankChief Scientific Officer26,210Jun 17, 20266
Mehta VimalCEO and President69,817Jun 17, 20266
Rodriguez JavierSee Remarks26,838Jun 17, 20266
Miller Michael PatrickDirector–Jan 12, 20261
Mueller PeterDirector–Jan 12, 20261
Patni RajivDirector–Jan 12, 20261
Votruba MichalDirector–Jan 12, 20261
Mack David J.Director20,317Jan 12, 20263
Laumas SandeepDirector–Jan 12, 20261
Bray JuneDirector–Jan 12, 20261
O'Neill VincentOther: See Remarks19,957Apr 1, 20250
Wiley Matthew T.Other: See Remarks19,011Apr 1, 20250
BioXcel LLC10% Owner7,685,501IndirectJun 6, 20240
BioXcel Holdings, Inc.10% Owner7,685,501IndirectJun 6, 20240
Nandabalan KrishnanDirector, 10% Owner0Apr 10, 20230
Kane William P JrChief Commercial Officer–Aug 18, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 22, 2026 (view filing)May 202 daysYocca FrankChief Scientific OfficerSSale−6.84K$1.09−$7.46K−20.7%26.2K after10b5-1
May 22, 2026 (view filing)May 202 daysRodriguez JavierSee RemarksSSale−6.56K$1.08−$7.08K−19.7%26.8K after10b5-1
May 22, 2026 (view filing)May 202 daysSteinhart Richard IChief Financial OfficerSSale−6.84K$1.09−$7.46K−20.7%26.3K after10b5-1
May 22, 2026 (view filing)May 202 daysMehta VimalCEO and PresidentSSale−19.4K$1.09−$21.2K−21.8%69.6K after10b5-1
Dec 17, 2024 (view filing)6:10 PM ETDec 161 dayO'Neill VincentSee RemarksSSale−165$0.3523−$58.13−0.8%20.0K after10b5-1
Dec 17, 2024 (view filing)6:08 PM ETDec 161 dayMehta VimalCEO and PresidentSSale−3.12K$0.3629−$1.13K−5.0%59.6K after2 lots10b5-1
Dec 17, 2024 (view filing)6:06 PM ETDec 161 daySteinhart Richard IChief Financial OfficerSSale−577$0.3587−$206.98−2.7%20.9K after2 lots10b5-1
Dec 17, 2024 (view filing)6:04 PM ETDec 161 dayRodriguez JavierSee RemarksSSale−430$0.3559−$153.02−1.7%24.4K after2 lots10b5-1
Dec 17, 2024 (view filing)6:03 PM ETDec 161 dayYocca FrankChief Scientific OfficerSSale−430$0.3531−$151.82−1.5%28.9K after2 lots10b5-1
Oct 3, 2024 (view filing)Oct 3Same dayWiley Matthew T.Chief Commercial OfficerSSale−6.27K$0.55−$3.45K−24.8%19.0K after10b5-1
Oct 3, 2024 (view filing)Oct 3Same dayRodriguez JavierSee RemarksSSale−6.86K$0.55−$3.77K−22.4%23.8K after10b5-1
Oct 3, 2024 (view filing)Oct 3Same dayYocca FrankChief Scientific OfficerSSale−7.17K$0.55−$3.95K−20.2%28.3K after10b5-1
Oct 3, 2024 (view filing)Oct 3Same daySteinhart Richard IChief Financial OfficerSSale−7.17K$0.55−$3.95K−26.1%20.3K after10b5-1
Oct 3, 2024 (view filing)Oct 3Same dayO'Neill VincentSee RemarksSSale−5.56K$0.55−$3.06K−22.1%19.6K after10b5-1
Sep 17, 2024 (view filing)Sep 161 dayYocca FrankChief Scientific OfficerSSale−355$0.69−$244.95−2.4%14.2K after10b5-1
Sep 17, 2024 (view filing)Sep 161 dayMehta VimalCEO and PresidentSSale−1.98K$0.69−$1.37K−3.7%51.7K after2 lots10b5-1
Sep 17, 2024 (view filing)Sep 161 daySteinhart Richard IChief Financial OfficerSSale−356$0.69−$245.64−5.4%6.20K after10b5-1
Sep 17, 2024 (view filing)Sep 161 dayRodriguez JavierSee RemarksSSale−345$0.69−$238.05−3.6%9.13K after10b5-1
Sep 17, 2024 (view filing)Sep 161 dayO'Neill VincentSee RemarksSSale−138$0.69−$95.22−3.4%3.91K after10b5-1
Sep 17, 2024 (view filing)Sep 161 dayWiley Matthew T.Chief Commercial OfficerSSale−215$0.69−$148.35−5.1%4.03K after10b5-1
Jun 18, 2024 (view filing)Jun 171 dayWiley Matthew T.Chief Commercial OfficerSSale−244$1.26−$307.44−6.5%3.50K afterAmended
Jun 18, 2024 (view filing)Jun 171 dayYocca FrankChief Scientific OfficerSSale−372$1.28−$476.16−2.7%13.5K after10b5-1
Jun 18, 2024 (view filing)Jun 171 daySteinhart Richard IChief Financial OfficerSSale−372$1.26−$468.72−6.4%5.48K after10b5-1
Jun 18, 2024 (view filing)Jun 171 dayRodriguez JavierSee RemarksSSale−361$1.26−$454.86−4.1%8.39K after10b5-1
Jun 18, 2024 (view filing)Jun 171 dayO'Neill VincentSee RemarksSSale−155$1.29−$199.95−4.2%3.52K after10b5-1
Jun 18, 2024 (view filing)Jun 171 dayMehta VimalCEO and PresidentSSale−2.13K$1.28−$2.73K−4.3%47.5K after10b5-1
Jun 6, 2024 (view filing)8:35 PM ETJun 4-52 daysMehta Vimal and 2 othersCEO and PresidentSSale−1.43M$1.61−$405.1K−15.7%7.69M after5 lots
Jun 6, 2024 (view filing)8:35 PM ETJun 42 daysMehta Vimal and 2 othersCEO and PresidentSSale−17.9K–––120 afterDerivative
Apr 8, 2024 (view filing)Apr 44 daysO'Neill VincentSee RemarksSSale−165$2.62−$432.3−3.0%5.41K after10b5-1
Apr 8, 2024 (view filing)Apr 44 daysMehta VimalCEO and PresidentSSale−5.27K$2.62−$13.8K−10.8%43.6K after2 lots10b5-1
Apr 8, 2024 (view filing)Apr 44 daysSteinhart Richard IChief Financial OfficerSSale−1.07K$2.64−$2.82K−18.3%4.76K after10b5-1
Apr 8, 2024 (view filing)Apr 44 daysWiley Matthew T.CHIEF COMMERCIAL OFFICERSSale−1.01K$2.64−$2.66K−25.2%2.99K after10b5-1
Apr 8, 2024 (view filing)Apr 44 daysRodriguez JavierSee RemarksSSale−1.01K$2.64−$2.67K−11.7%7.67K after10b5-1
Apr 8, 2024 (view filing)Apr 44 daysYocca FrankChief Scientific OfficerSSale−1.07K$2.64−$2.82K−7.7%12.8K after10b5-1
Jun 16, 2023 (view filing)6:40 PM ETJun 15-161 dayMehta VimalCEO and PresidentSSale−60.0K$20.86−$1.25M−60.1%39.9K after5 lots10b5-1
May 24, 2023 (view filing)May 222 daysMehta VimalCEO and PresidentSSale−6.50K$25.79−$167.6K−14.8%37.3K after10b5-1
May 16, 2023 (view filing)May 151 daySteinhart Richard IChief Financial OfficerSSale−5.00K$27.17−$135.8K−76.9%1.50K after10b5-1
May 16, 2023 (view filing)May 151 dayRodriguez JavierSee RemarksSSale−1.78K$27.32−$48.8K−29.1%4.35K after10b5-1
Apr 10, 2023 (view filing)6:20 PM ETApr 64 daysNandabalan KrishnanDirector, 10% OwnerSSale−60.0K$17.32−$1.04M−100.0%0 after10b5-1
Mar 22, 2023 (view filing)7:30 PM ETMar 20-212 daysMehta VimalCEO and PresidentSSale−64.5K$18.97−$1.22M−80.2%15.9K after6 lots
Mar 16, 2023 (view filing)Mar 151 dayO'Neill VincentSee RemarksSSale−845$19.70−$16.6K−40.5%1.24K afterAmended
Mar 16, 2023 (view filing)Mar 151 daySteinhart Richard IChief Financial OfficerSSale−2.08K$19.50−$40.6K−58.1%1.50K after
Mar 16, 2023 (view filing)Mar 151 dayYocca FrankChief Scientific OfficerSSale−985$19.69−$19.4K−9.4%9.50K after
Mar 16, 2023 (view filing)Mar 151 dayRodriguez JavierSee RemarksSSale−950$19.63−$18.6K−45.6%1.14K after
Jan 24, 2023 (view filing)8:04 PM ETJan 204 daysO'Neill VincentChief Medical OfficerSSale−29.7K$30.00−$891.4K−100.0%0 after
Jan 24, 2023 (view filing)Jan 204 daysYocca FrankChief Scientific OfficerSSale−50.0K$30.00−$1.50M−85.6%8.40K after
Jan 6, 2023 (view filing)8:00 PM ETJan 4-52 daysNandabalan KrishnanDirector, 10% OwnerSSale−60.0K$22.01−$1.32M−100.0%0 after4 lots
Dec 19, 2022 (view filing)8:00 PM ETDec 15-164 daysMehta VimalCEO and PresidentSSale−60.0K$19.69−$1.18M−85.8%9.96K after4 lots
Nov 14, 2022 (view filing)8:00 PM ETNov 10-114 daysNandabalan KrishnanDirector, 10% OwnerSSale−60.0K$15.00−$900.0K−100.0%0 after2 lots